Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinoma in situ

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    479 result(s) found for: Carcinoma in situ. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-003575-18 Sponsor Protocol Number: ICO-2020-06 Start Date*: 2020-12-08
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
    Medical condition: Patients with extensive ductal carcinoma in situ with an indication for total mastectomy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006189 Breast cancer in situ PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018246-38 Sponsor Protocol Number: Jun_11_2009_Updated_Nov_2009 Start Date*: 2010-12-23
    Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder
    Medical condition: patients with muscle invasive transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005017 Bladder carcinoma stage 0, with cancer in situ LLT
    12.1 10005019 Bladder carcinoma stage I, with cancer in situ LLT
    12.1 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023271-26 Sponsor Protocol Number: MI-CI-C02 Start Date*: 2011-02-01
    Sponsor Name:Mithra Pharmaceuticals SA
    Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl...
    Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007763-16 Sponsor Protocol Number: 1.0 Start Date*: 2009-05-06
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie
    Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia
    Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004189-37 Sponsor Protocol Number: HCQHNLcancer Start Date*: 2022-03-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer
    Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078181 Laryngeal squamous cell carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030964 Oral carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037352 Pulmonary carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025122 Lung squamous cell carcinoma stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005428-99 Sponsor Protocol Number: 08/0365 Start Date*: 2009-10-19
    Sponsor Name:University College London
    Full Title: A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b...
    Medical condition: Non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005006 Bladder cancer stage 0, with cancer in situ LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005008 Bladder cancer stage I, with cancer in situ LLT
    9.1 10005009 Bladder cancer stage I, without cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001236-28 Sponsor Protocol Number: R39_21_01 Start Date*: 2023-01-13
    Sponsor Name:Fidia Farmaceutici S.p.A.
    Full Title: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG-unresponsive Carcinoma in Si...
    Medical condition: BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007400 Carcinoma in situ of the bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000318-12 Sponsor Protocol Number: MITOCERV3 Start Date*: 2020-02-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006088-22 Sponsor Protocol Number: Gastripec-I Start Date*: 2011-03-28
    Sponsor Name:Klinik für Chirurgie, Charité Campus Virchow-Klinikum
    Full Title: Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carc...
    Medical condition: Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10042080 Stomach cancer LLT
    20.0 100000004864 10042081 Stomach cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006946-24 Sponsor Protocol Number: NV25025 Start Date*: 2009-12-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high...
    Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2014-002336-14 Sponsor Protocol Number: Start Date*: 2014-09-05
    Sponsor Name:University Hosptial Bristol NHS Foundation trust
    Full Title: A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.
    Medical condition: Relapsed, locally advanced and/or metastatic carcinoma of the penis.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007384 Carcinoma in situ of penis PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-004112-28 Sponsor Protocol Number: URO-EMDA-2022-1 Start Date*: 2023-03-27
    Sponsor Name:Guillem Abad Carratalà
    Full Title: Randomized prospective study of the impact of preoperative instillation of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle-infiltrating urothelial carcinoma
    Medical condition: Non muscle invasive bladder tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005009 Bladder cancer stage I, without cancer in situ PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002372-18 Sponsor Protocol Number: 515 Start Date*: 2006-09-11
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer.
    Medical condition: Bladder Cancer Stage 1 without Cancer in Situ Patients will have transitional-cell carcinoma of the bladder, clinical TNM stage Ta or T1 and histologic grade G1 or G2 before transurethral resection.
    Disease: Version SOC Term Classification Code Term Level
    9 10005009 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005377-31 Sponsor Protocol Number: ISRCTN45751386 Start Date*: 2016-01-20
    Sponsor Name:HYKS Naistensairaala
    Full Title: Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN)
    Medical condition: VAIN, vaginal intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046890 Vaginal cancer stage 0 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000746-59 Sponsor Protocol Number: ISRCTN23349576 Start Date*: 2016-02-18
    Sponsor Name:HYKS Naistensairaala
    Full Title: Randomized trial of treatment of vaginal intraepithelial neoplasia (VAIN).
    Medical condition: VAIN, vaginal intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046890 Vaginal cancer stage 0 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008251-42 Sponsor Protocol Number: 26014 Start Date*: 2009-09-07
    Sponsor Name:Erasmus MC
    Full Title: Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN
    Medical condition: In this trial, the efficacy of Gardasil combined with imiquimod in women with usual type Vulvar Intraepithelial Neoplasia is investigated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047778 Vulvar cancer in situ LLT
    9.1 10066416 Vulvovaginal human papilloma virus infection LLT
    9.1 10046859 Vaccination LLT
    9.1 10062059 Histology abnormal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002979-26 Sponsor Protocol Number: D419JC00001 Start Date*: 2018-07-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Musc...
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005008 Bladder cancer stage I, with cancer in situ PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Restarted) FR (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004465-33 Sponsor Protocol Number: Cox052006 Start Date*: 2006-12-04
    Sponsor Name:Eero Kaasinen
    Full Title: Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder
    Medical condition: invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005014 Bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-003495-31 Sponsor Protocol Number: CCLL442X2201 Start Date*: 2017-12-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w...
    Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:11:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA